1. Gerbert B, Love C, Caspers N, Linkins K, Burack J. Making all the difference in the world”: How physicians can help HIV-seropositive patients become more involved in their health care. AIDS Patient Care STDs. 1999;13:29–39. [PubMed] 2. Gerbert B, Brown B, Volberding P, et al. Physicians’ transmission prevention assessment and counseling practices with their HIV positive patients. AIDS Educ Prev. 1999;11:307–320. [PubMed] 3. Gerbert B, Herzig K, Volberding P, Stansell J. Perceptions of health care professionals and patients about the risk of HIV transmission through oral sex: A qualitative study. Patient Educ Couns. 1997;38:49–60. [PubMed] 4. Gerbert B, Bronstone A, Clanon K, Abercrombie P, Bangsberg D. Combination antiretroviral therapy: Health care providers confront emerging dilemmas. AIDS Care. 2000;12:409–421. [PubMed] 5. Gerbert B, Moe J, Saag M, et al. Toward a definition of HIV expertise: A survey of experienced HIV physicians. AIDS Pat Care STDS. 2001;15:321–330. [PubMed] 6. Gerbert B, Gansky S, Tang JW, et al. Domestic violence compared to other health risks: A survey of physicians’ beliefs and behaviors. Am J Prev Med. 2002;23:82–90. [PubMed] 7. Schlitz MA, Sandfort TGM. HIV-positive people, risk and sexual behavior. Soc Sci Med. 2000;50:1571–1588. [PubMed] 8. Centers for Disease Control and Prevention. Incorporating HIV prevention into the medical care of persons living with HIV. MMWR. 2003;52:1–24. [PubMed] 9. Centers for Disease Control and Prevention. Advancing HIV prevention: New strategies for a changing epidemic—United States, 2003. MMWR. 2003;52:329–332. [PubMed] 10. Aberg JA, Gallant JE, Anderson J, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2004;39:609–629. [PubMed]
11. Roehr B. Community reps strike back at CDC during prevention confab. Bay Area Reporter. 2003 August;
12. Russell S. AIDS prevention groups fear U.S. funding cuts. San Francisco Chronicle. 2003 July 26;:A4.
13. Zierler S, Cunningham WE, Andersen R, et al. Violence victimization after HIV infection in a US probability sample of adult patients in primary care. Am J Public Health. 2000;90:208–215. [PubMed] 14. Bayer R. AIDS prevention—Sexual ethics and responsibility. N Engl J Med. 1996;334:1540–1542. [PubMed] 15. Ciccarone DH, Kanouse DE, Collins RL, et al. Sex without disclosure of positive HIV serostatus in a US probability sample of persons receiving medical care for HIV infection. Am J Public Health. 2003;93:949–954. [PubMed] 16. Gerbert B, Bleecker T, Maguire BT, Caspers N. Physicians and AIDS: sexual risk assessment of patients and willingness to treat HIV-infected patients. J Gen Intern Med. 1992;7:657–664. [PubMed]
17. Lloyd GA, Kuszelewicz MD. HIV Disease: Lesbians, Gays, and the Social Services. New York: The Haworth Press; 1995.
18. Cooke M. Supporting health care workers in the treatment of HIV-infected patients. Prim Care. 1992;19:245–256. [PubMed] 19. Carr GS. Negotiating trust: A grounded theory study of interpersonal relationships between persons living with HIV/AIDS and their primary health care providers. J Assoc Nurses AIDS Care. 2001;12:35–43. [PubMed] 20. Kassler WJ, Wu AW. Addressing HIV infection in office practice: Assessing risk, counseling, and testing. Prim Care. 1992;19:19–33. [PubMed] 21. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. [Last accessed April 18, 1979]. www.ohsr.od.nih.gov/guidelines/belmont.html. 22. Metsch LR, Pereyra M, del Rio C, et al. Delivery of HIV prevention counseling by physicians at HIV medical care settings in 4 US cities. Am J Public Health. 2004;94:1186–1192. [PubMed] 23. Centers for Disease Control and Prevention. Increases in HIV Diagnoses—29 States, 1999–2002. MMWR. 2003;52:1145–1148. [PubMed] 24. Clottey C, Dallabetta G. Sexually transmitted diseases and human immunodeficiency virus. Epidemiologic synergy? Infect Dis Clin North Am. 1993;7:753–770. [PubMed] 25. Novak RM, Chen L, MacArthur RD, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: Implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis. 2005;40:468–474. [PubMed]
26. Markowitz M, Mohri H, Mehandru S, et al. A case of apparent recent infection with a multi-drug-resistant and dual-tropic HIV-1 in association with rapid progression to AIDS. Paper presented at: 12th Conference on Retroviruses and Opportunistic Infections; Boston, MA. 2005.
27. Stover CT, Smith DK, Schmid DS, et al. Prevalence of and risk factors for viral infections among human immunodeficiency virus (HIV)-infected and high-risk HIV-uninfected women. J Infect Dis. 2003;187:1388–1396. [PubMed] 28. Bartlett JG. Recent developments in the management of herpes simplex virus infection in HIV-infected persons. Clin Infect Dis. 2004;39:S237–S239. [PubMed] 29. Murphy MJ, Wilcox RD. Management of the coinfected patient: human immunodeficiency virus/hepatitis B and human immunodeficiency virus/hepatitis C. Am J Med Sci. 2004;328:26–36. [PubMed] 30. Thio CL, Seaberg EC, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) Lancet. 2002;360:1921–1926. [PubMed] 31. Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: Recommendations from an HIV-HBV International Panel. AIDS. 2005;19:221–240. [PubMed] 32. Immunization Practices Advisory Committee. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR. 1991;40:1–19. [PubMed] 33. Ristola MA, Vuola JM, Valle M, von Reyn CF. Antibody responses to intradermal recombinant hepatitis B immunization among HIV-positive subjects. Vaccine. 2004;23:205–209. [PubMed]
34. Hecht FM. Immunizations in HIV infection. In: Cohen PT, Sande MA, Volberding PA, editors. The AIDS Knowledge Base. Philadelphia: Lippincott Williams & Wilkins; 1999. pp. 235–239.
35. Chaix ML, Serpaggi J, Batisse D, et al. Phylogenetic analysis reveals a cluster of genotype 4 HCV transmitted by sexual intercourse in HIV-1 infected men. Paper presented at: 55th Annual Meeting of the American Association for the Study of Liver Diseases; Boston, MA. 2004.
36. Centers for Disease Control and Prevention. HIV Prevention Saves Lives: Drug Association Transmission Continues in the United States: Division of HIV/AIDS Prevention. January 31, 2001.
37. Ebright JR, Pieper B. Skin and soft tissue infections in injection drug users. Infect Dis Clin North Am. 2002;16:697–712. [PubMed] 38. Kimura AC, Higa JI, Levin RM, Simpson G, Vargas Y, Vugia DJ. Outbreak of necrotizing fasciitis due to Clostridrium sordellii among black-tar heroin users. Clin Infect Dis. 2004;38:e87–91. [PubMed] 39. Warner RM, Srinivasan JR. Protean manifestations of intravenous drug use. Surgeon. 2004;2:137–140. [PubMed] 40. Kak V, Chandrasekar PH. Bone and joint infections in injection drug users. Infect Dis Clin North Am. 2002;16:681. [PubMed] 41. Risdahl JM, Khanna KV, Peterson PK, Molitor TW. Opiates and infection. J Neuroimmunol. 1998;83:4–18. [PubMed] 42. Wood E, Montaner JSG, Yip B, et al. Adherence and plasma HIV RNA responses to highly active anti-retroviral therapy among HIV-1 infected injection drug users. Can Med Assoc J. 2003;169:656–661. [PMC free article] [PubMed] 43. Celetano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280:544–546. [PubMed] 44. Moore R, Keruly J, Chaisson R. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr. 2004;35:46–51. [PubMed]
45. Lawrence SP. Advances in the treatment of Hepatitis C. In: Schrier R, editor. Advances in Internal Medicine. Vol. 45. Chicago, IL: Mosby-Yearbook, Inc; 2000. pp. 65–105.
46. Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas C. Hepatitis C virus is related to progressive liver disease in HIV-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis. 1999;179:1254–1258. [PubMed] 47. Anderson KB, Guest JL, Rimland D. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: Data from the HIV Atlanta VA Cohort Study. Clin Infect Dis. 2004;39:1507–1513. [PubMed] 48. Sherman KE, Rouster SD, Chung RT, Jajicic N. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: A cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831–837. [PubMed] 49. Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C Virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology. 2001;34:180–187. [PubMed] 50. Williams I. Epidemiology of hepatitis C in the United States. Am J Med. 1999;107:2S–9S. [PubMed] 51. Hays RB, Paul J, Ekstrand M, Kegeles SM, Stall R, Coates TJ. Actual versus perceived HIV status, sexual behaviors and predictors of unprotected sex among young gay and bisexual men who identify as HIV-negative, HIV-positive and untested. AIDS. 1997;11:1495–1502. [PubMed] 52. Kalichman SC, Kelly JA, Rompa D. Continued high-risk sex among HIV seropositive gay and bisexual men seeking HIV prevention services. Health Psychol. 1997;16:369–373. [PubMed] 53. Molitor F, Truax SR, Ruiz JD, Sun RK. Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. West J Med. 1998;168:93–97. [PMC free article] [PubMed] 54. Hoffman JA, Klein H, Eber M, Crosby H. Frequency and intensity of crack use as predictors of women’s involvement in HIV-related sexual risk behaviors. Drug Alcohol Depend. 2000;58:227–236. [PubMed] 55. Logan TK, Leukefeld C. Sexual and drug use behaviors among female crack users: A multi-site sample. Drug Alcohol Depend. 2000;58:237–245. [PubMed] 56. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251–259. [PubMed] 57. Burnam MA, Bing EG, Morton SC, et al. Use of mental health and substance abuse treatment services among adults with HIV in the United States. Arch Gen Psychiatry. 2001;58:729–736. [PubMed]
58. Francis H. Management of substance abuse. In: Bartlett JG, Cheever LW, Johnson MP, Paauw DS, editors. A Guide to Primary Care of People with HIV/AIDS. Washington D.C: U.S. Department of Health and Human Services, Health Resources and Services Administration, HIV/AIDS Bureau; 2004. pp. 105–114.
59. U.S. Department of Health and Human Services. Healthy People 2010. 2. Washington, DC: International Medical Publishing Inc; 2000.
60. Cohen MH, Cook JA, Grey D, et al. Medically eligible women who do not use HAART: The importance of abuse, drug use, and race. Am J Public Health. 2004;94:1147–1151. [PubMed] 61. Lucas G, Gebo K, Chaisson R, Moore R. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16:767–774. [PubMed] 62. Wall TL, Sorensen JL, Batki SL. Adherence to zidovudine (AZT) among HIV-infected methadone patients: A pilot study of supervised therapy and dispensing compared to usual care. Alcohol Depend. 1995;37:261–269. [PubMed]
63. Batki SL, Sorensen JL. Care of injection drug users. HIV Insite Knowledge Base; University of California San Francisco: 1998.
64. Laine C, Hauck WW, Gourevitch MN, Rothman J, Cohen A, Turner BJ. Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs. JAMA. 2001;285:2355–2362. [PubMed] 65. King VL, Kidorf MS, Stoller KB, Brooner RK. Influence of psychiatric comorbidity on HIV risk behaviors: Changes during drug abuse treatment. J Addict Dis. 2000;19:65–83. [PubMed] 66. Galvan FH, Bing EG, Fleishman JA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: Results from the HIV Cost and Services Utilization Study. J Stud Alcohol. 2002;63:179–186. [PubMed]
67. National Institute on Alcohol Abuse and Alcoholism. The Physicians’ Guide to Helping Patients with Alcohol Problems. Vol NIH Publication No. 95-3769. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health; 1995.
68. Cook RL, Sereika SM, Hunt SC, Woodward WC, Erlen JA, Conigliaro J. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med. 2001;16:83–88. [PMC free article] [PubMed] 69. McCusker J, Westenhouse J, Stoddard AM, Zapka JG, Zorn MW, Mayer KH. Use of drugs and alcohol by homosexually active men in relation to sexual practices. J Acquir Immune Defic Syndr. 1990;3:729–736. [PubMed] 70. Avins AL, Lindan CP, Woods WJ, et al. Changes in HIV-related behaviors among heterosexual alcoholics following addiction treatment. Drug Alcohol Depend. 1997;44:47–55. [PubMed] 71. Ericksen KP, Trocki KF. Sex, alcohol and sexually transmitted diseases: A national survey. Fam Plann Perspect. 1994;26:257–263. [PubMed] 72. Emmons KM, Rollnick S. Motivational interviewing in health care settings: Opportunities and limitations. Am J Prev Med. 2001;20:68–74. [PubMed]
73. Rollnick S, Mason P, Butler C. Health Behavior Change: A Guide for Practitioners. Edinburgh; Churchill Livingstone: 1999.
74. Rollnick S, Miller W. What is motivational interviewing? Behav Cognitive Psychother. 1995;23:325–334.
75. Hollis J, Lichtenstein E, Vogt T, Stevens V, Biglan A. Nurse-assisted counseling for smokers in primary care. Ann Intern Med. 1993;118:521–525. [PubMed]
76. Butler CC, Rollnick S, Cohen D, Bachmann M, Russell I, Stott N. Motivational consulting versus brief advice for smokers in general practice: A randomized trial. Br J Gen Pract. 1999;49:611–616.
77. Miller W, Benefield R, Tonigan J. Enhancing motivation for change in problem drinking: A controlled comparison of two therapist styles. J Consult Clin Psychol. 1993;61:455–461. [PubMed] 78. Senft R, Polen M, Freeborn D, Hollis J. Brief intervention in a primary care setting for hazardous drinkers. Am J Prev Med. 1997;13:464–470. [PubMed] 79. Heather N, Rollnick S, Bell A, Richmond R. Effects of brief counseling among male heavy drinkers identified on general hospital wards. Drug Alcohol Recov. 1996;15:29–38. [PubMed]
80. Miller W, Sanchez V. Motivating young adults for treatment and lifestyle change. In: Howard G, editor. Issues in Alcohol Use and Misuse by Young Adults. Notre Dame, IN: University of Notre Dame Press; 1994. pp. 55–82.
81. Miller WR, Rollnick S. Motivational Interviewing: Preparing People to Change Addictive Behaviors. New York: Guilford Press; 1991.
82. Stewart M. Effective physician-patient communication and health outcomes. Can Med Assoc J. 1995;152:1423–1433. [PMC free article] [PubMed]
83. Coates TJ, Cummings SR. Behavior modification. In: Kassirer JP, editor. Current Therapy in Internal Medicine. 3. Philadelphia, PA: Mosby-Year Book; 1991. pp. 79–83.
84. Bandura A. Self-efficacy: Toward a unifying theory of behavioral change. Psychol Rev. 1977;84:191–215. [PubMed] 85. Gerbert B, Berg-Smith S, Mancuso M, McPhee SJ, Null D, Wofsy J. Using innovative video doctor technology in primary care to deliver brief smoking and alcohol intervention. Health Promot Pract. 2003;4:249–261. [PubMed] 86. Barnes HN, Samet J. Brief interventions with substance-abusing patients. Med Clin North Am. 1997;81:867–878. [PubMed] 87. Willms DG, Best JA, Wilson DM, et al. Patients’ perspectives of a physician-delivered smoking cessation intervention. Am J Prev Med. 1991;7:95–100. [PubMed] 89. Gerbert B, Bleecker T, Bernzweig J. Is anybody talking to physicians about acquired immunodeficiency syndrome and sex? A national survey of patients. Arch Fam Med. 1993;2:45–51. [PubMed] 90. Morin SF, Koester KA, Steward WT, et al. Missed opportunities: prevention with HIV-infected patients in clinical care settings. J Acquire Immune Defic Syndr. 2004;36:960–966. [PubMed] 91. Gerbert B, Abercrombie P, Caspers N, Love C, Bronstone A. How health care providers help battered women: The survivors perspective. Women Health. 1999;29:115–135. [PubMed] 92. Rabkin JG, Ferrando S. A ‘second life’ agenda. Psychiatric research issues raised by protease inhibitor treatments for people with the human immunodeficiency virus or the acquired immunodeficiency syndrome. Arch Gen Psych. 1997;54:1049–1053. [PubMed]